If you were treated for cancer five, ten, or even twenty years ago and no one ever mentioned genetic testing, you are not alone. For many cancer survivors, hereditary risk evaluation simply was not part of standard care at the time of their diagnosis. That has changed dramatically.

Why Guidelines Have Changed

Broader criteria. Organizations like the NCCN have steadily expanded who should be offered testing. In 2024, guidelines were updated to recommend BRCA testing for all breast cancer patients diagnosed at age 65 or younger.

More genes, better understanding. When you were diagnosed, testing may have been limited to BRCA1 and BRCA2. Today, multi-gene panels examine 40 to 80 or more genes.

Lower cost, greater access. The cost of comprehensive genetic testing has decreased from several thousand dollars to a few hundred, and insurance coverage has expanded substantially.

What Testing Can Reveal for Survivors

  • Surveillance for second cancers. Many hereditary variants increase risk for multiple cancer types. Knowing your status enables your care team to implement appropriate surveillance.
  • Treatment implications for recurrence. If your cancer recurs, knowing your hereditary status could expand treatment options, including PARP inhibitors.
  • Family implications. If your cancer was caused by a hereditary variant, your children, siblings, and other blood relatives may carry the same variant. Learn more about cascade testing for families.

Should You Get Tested?

Free 60-second screener based on NCCN guidelines — no account needed

Check Your Eligibility →

Common Diagnoses Where Testing Is Now Recommended

  • Breast cancer diagnosed at age 65 or younger
  • Ovarian, fallopian tube, or primary peritoneal cancer at any age
  • Triple-negative breast cancer at any age
  • Colorectal cancer diagnosed before age 50
  • Endometrial cancer diagnosed before age 50
  • Pancreatic cancer at any age
  • Male breast cancer at any age
  • Prostate cancer that was metastatic or high-grade (Gleason 7+)
  • Multiple primary cancers

If you are uncertain whether your diagnosis qualifies, see who should consider genetic testing.

It Is Not Too Late

The value of genetic testing is not limited to the moment of diagnosis. The information is encoded in your DNA and does not change with time. A clinical risk assessment is a simple, confidential first step. Learn about understanding your results.